دورية أكاديمية
أعرض في EDS

Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin.

التفاصيل البيبلوغرافية
العنوان: Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin.
المؤلفون: Ma G; Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom., Crowley AR; Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom., Heyndrickx L; argenx, Zwijnaarde, Ghent, Belgium., Rogiers I; argenx, Zwijnaarde, Ghent, Belgium., Parthoens E; VIB BioImaging Core, Center for Inflammation Research, Ghent, Belgium., Van Santbergen J; argenx, Zwijnaarde, Ghent, Belgium., Ober RJ; Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom., Bobkov V; argenx, Zwijnaarde, Ghent, Belgium., de Haard H; argenx, Zwijnaarde, Ghent, Belgium., Ulrichts P; argenx, Zwijnaarde, Ghent, Belgium., Hofman E; argenx, Zwijnaarde, Ghent, Belgium., Louagie E; argenx, Zwijnaarde, Ghent, Belgium., Balbino B; argenx, Zwijnaarde, Ghent, Belgium., Ward ES; Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
المصدر: JCI insight [JCI Insight] 2024 May 07; Vol. 9 (10). Date of Electronic Publication: 2024 May 07.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Ann Arbor, Michigan : American Society for Clinical Investigation, [2016]-
مواضيع طبية MeSH: Receptors, Fc*/metabolism , Histocompatibility Antigens Class I*/metabolism, Humans ; Immunoglobulin G/metabolism ; Animals ; Protein Transport/drug effects ; Serum Albumin/metabolism ; Mice ; Protein Binding
مستخلص: The homeostasis of IgG is maintained by the neonatal Fc receptor, FcRn. Consequently, antagonism of FcRn to reduce endogenous IgG levels is an emerging strategy for treating antibody-mediated autoimmune disorders using either FcRn-specific antibodies or an engineered Fc fragment. For certain FcRn-specific antibodies, this approach has resulted in reductions in the levels of serum albumin, the other major ligand transported by FcRn. Cellular and molecular analyses of a panel of FcRn antagonists have been carried out to elucidate the mechanisms leading to their differential effects on albumin homeostasis. These analyses have identified 2 processes underlying decreases in albumin levels during FcRn blockade: increased degradation of FcRn and competition between antagonist and albumin for FcRn binding. These findings have potential implications for the design of drugs to modulate FcRn function.
References: Kidney Int. 2016 Jul;90(1):41-52. (PMID: 27165836)
Nat Commun. 2018 Feb 12;9(1):621. (PMID: 29434196)
Nat Commun. 2012 Jan 03;3:610. (PMID: 22215085)
Mol Biol Cell. 2013 Aug;24(15):2398-405. (PMID: 23741050)
Front Immunol. 2019 Jul 10;10:1540. (PMID: 31354709)
Annu Rev Genet. 2009;43:67-93. (PMID: 19653858)
J Cell Biol. 2018 Oct 1;217(10):3640-3655. (PMID: 30018090)
J Biol Chem. 1975 Mar 25;250(6):2333-8. (PMID: 234968)
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9337-42. (PMID: 18599440)
J Immunol. 2004 Feb 15;172(4):2021-9. (PMID: 14764666)
Lancet Neurol. 2023 May;22(5):383-394. (PMID: 37059507)
Ther Adv Ophthalmol. 2021 Jun 30;13:25158414211027760. (PMID: 34263138)
Nature. 1989 Jan 12;337(6203):184-7. (PMID: 2911353)
Traffic. 2006 Sep;7(9):1127-42. (PMID: 17004319)
J Mol Biol. 1992 Mar 20;224(2):487-99. (PMID: 1560463)
Nat Biotechnol. 2005 Oct;23(10):1283-8. (PMID: 16186811)
Mol Immunol. 1996 Apr;33(6):521-30. (PMID: 8700168)
Biochemistry. 1995 Nov 14;34(45):14649-57. (PMID: 7578107)
J Thromb Thrombolysis. 2020 Nov;50(4):1004-1011. (PMID: 32279215)
Eur J Immunol. 1994 Oct;24(10):2429-34. (PMID: 7925571)
J Clin Endocrinol Metab. 2023 Nov 17;108(12):3122-3134. (PMID: 37390454)
Sci Transl Med. 2017 Nov 1;9(414):. (PMID: 29093180)
J Immunol. 2007 Apr 15;178(8):5390-8. (PMID: 17404325)
J Biol Chem. 1972 Nov 10;247(21):7038-42. (PMID: 5082140)
J Clin Invest. 2018 Oct 1;128(10):4372-4386. (PMID: 30040076)
Int J Biol Macromol. 2020 Dec 1;164:3474-3484. (PMID: 32882278)
MAbs. 2015;7(2):344-51. (PMID: 25654695)
Am J Reprod Immunol. 2018 Sep;80(3):e12972. (PMID: 29745444)
J Biol Chem. 2006 Aug 18;281(33):23514-24. (PMID: 16793771)
Int Immunol. 1998 Sep;10(9):1289-98. (PMID: 9786428)
J Immunol. 2009 Jun 15;182(12):7663-71. (PMID: 19494290)
Int Immunol. 2003 Feb;15(2):187-95. (PMID: 12578848)
Eur J Immunol. 1985 Jul;15(7):733-8. (PMID: 2988974)
Theor Biol Med Model. 2013 Mar 18;10:20. (PMID: 23506635)
Mol Biol Cell. 2004 Apr;15(4):1746-59. (PMID: 14767057)
MAbs. 2012 Mar-Apr;4(2):208-16. (PMID: 22453095)
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5889-94. (PMID: 17384151)
Front Immunol. 2015 Apr 23;6:176. (PMID: 25954273)
Biochim Biophys Acta. 2013 Dec;1830(12):5435-43. (PMID: 23665585)
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jan 1;845(1):157-63. (PMID: 16962833)
Int Immunol. 2001 Aug;13(8):993-1002. (PMID: 11470769)
J Biol Chem. 2002 Aug 2;277(31):28038-50. (PMID: 12023961)
Arthritis Rheum. 2010 Jun;62(6):1755-62. (PMID: 20191576)
Clin Pharmacol Ther. 2019 Apr;105(4):1031-1039. (PMID: 30402880)
J Cell Sci. 2018 Jul 6;131(13):. (PMID: 29980602)
Eur J Immunol. 1996 Jul;26(7):1527-31. (PMID: 8766556)
J Clin Invest. 1999 Oct;104(7):903-11. (PMID: 10510331)
Neurol Ther. 2022 Jun;11(2):815-834. (PMID: 35412216)
Front Neurosci. 2024 Feb 01;18:1302714. (PMID: 38362023)
J Cell Sci. 2019 Feb 19;132(5):. (PMID: 30700496)
Bioessays. 2022 Dec;44(12):e2200158. (PMID: 36344475)
Lancet Neurol. 2021 Jul;20(7):526-536. (PMID: 34146511)
Front Immunol. 2015 Jan 26;5:682. (PMID: 25674083)
Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2862-E2871. (PMID: 28330995)
Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11076-81. (PMID: 15258288)
Pharmaceutics. 2021 Aug 05;13(8):. (PMID: 34452168)
J Immunol. 2001 Mar 1;166(5):3266-76. (PMID: 11207281)
Front Immunol. 2022 Jun 01;13:892534. (PMID: 35757719)
Pathobiology. 1993;61(5-6):283-7. (PMID: 8297494)
Nat Rev Immunol. 2023 Jul;23(7):415-432. (PMID: 36726033)
Trends Pharmacol Sci. 2018 Oct;39(10):892-904. (PMID: 30143244)
J Lipid Res. 2013 Mar;54(3):671-676. (PMID: 23288948)
Nat Biotechnol. 1997 Jul;15(7):637-40. (PMID: 9219265)
J Exp Med. 2003 Feb 3;197(3):315-22. (PMID: 12566415)
Commun Biol. 2021 Mar 8;4(1):310. (PMID: 33686177)
Neurology. 2019 Jun 4;92(23):e2661-e2673. (PMID: 31118245)
N Engl J Med. 2006 Oct 26;355(17):1772-9. (PMID: 17065638)
Biochemistry. 2006 Apr 18;45(15):4983-90. (PMID: 16605266)
J Biol Chem. 2017 Aug 11;292(32):13312-13322. (PMID: 28637874)
Am J Physiol Renal Physiol. 2021 Nov 1;321(5):F572-F586. (PMID: 34541900)
Am J Med. 2002 Feb 15;112(3):247-8. (PMID: 11893361)
J Immunol. 2007 Oct 1;179(7):4580-8. (PMID: 17878355)
J Biol Chem. 2014 Mar 14;289(11):7812-24. (PMID: 24469444)
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2788-93. (PMID: 19188594)
Br J Dermatol. 2022 Mar;186(3):429-439. (PMID: 34608631)
Front Immunol. 2022 Nov 01;13:1054425. (PMID: 36389739)
Eur J Immunol. 2006 Nov;36(11):3044-51. (PMID: 17048273)
Biophys J. 1997 Nov;73(5):2782-90. (PMID: 9370472)
Sci Transl Med. 2020 Oct 14;12(565):. (PMID: 33055243)
Biochim Biophys Acta. 2013 Dec;1830(12):5494-502. (PMID: 23612153)
Nat Commun. 2022 Oct 14;13(1):6073. (PMID: 36241613)
MAbs. 2019 Jul;11(5):848-860. (PMID: 30964743)
فهرسة مساهمة: Keywords: Autoimmune diseases; Autoimmunity; Immunoglobulins; Immunology
المشرفين على المادة: 0 (Fc receptor, neonatal)
تواريخ الأحداث: Date Created: 20240507 Date Completed: 20240522 Latest Revision: 20240607
رمز التحديث: 20240608
مُعرف محوري في PubMed: PMC11141909
DOI: 10.1172/jci.insight.176166
PMID: 38713534
قاعدة البيانات: MEDLINE
الوصف
تدمد:2379-3708
DOI:10.1172/jci.insight.176166